The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector.

In May 2023, Vyjuvek was approved by the US FDA for the treatment of dystrophic epidermolysis bullosa (DEB). Vyjuvek is a non-invasive, topical, redosable gene therapy designed to treat DEB at the molecular level. This made it the first FDA-approved treatment for a rare, devastating skin disease.